|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Adalimumab, a fullyhuman anti-tumor necrosis factor alpha monoelonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitantmethotrexate: the ARMADA trial 显示文摘 | Weinblatt ME Keystone EC Furst DE | 2003 | Arthritis Rheum2003，48，： | 1 |
| 2 | Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study显示文摘 | Keystone EC Genovese MC Klareskog L | 2009 | Ann Rheum Dis2009，68，6： | 1 |
| 3 | Etanercept treatment in adults with established rheumatoid arthritis:7 years of clinical experience显示文摘 | Moreland LW Weinblatt ME Keystone EC | 2006 | J Rheum2006，33，5： | 1 |
| 4 | Update consensus statement on biological agents for the treatment of rheumatic disease显示文摘 | Furst DE Keystone EC Kirkham B | 2008 | Ann Rheum Dis2008，67，3： | 1 |
| 5 | Continued Benefit of Tocilizumab Plus Disease-modifying Antirheumatic Drug Therapy in Patients with Rheumatoid Arthritis and Inadequate Clinical Responses by Week 8of Treatment显示文摘 | Keystone EC Anisfeld A Ogale S | 2014 | J Rheumatol2014，41，： | 1 |
| 6 | Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial 显示文摘 | Weinblatt ME Keystone EC Furst DE | 2003 | Arthrtis Rheum2003，48，1： | 1 |
| 7 | Adalimumab, a fully human antitumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial 显示文摘 | Weinblatt ME Keystone EC Furst DE | 2003 | ArthritisRheum2003，48，1： | 1 |
| 8 | Radiogrphic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial显示文摘 | Keystone EC Kavanaugh AF Sharp JT | 2004 | Arthrtis Rheum2004，50，5： | 1 |
| 9 | Developing an effective treatment algo- rithm for rheumatoid arthritis显示文摘 | Keystone EC Smolen J | 2012 | Rheumatology(Oxford)2012，51，5： | 1 |
| 10 | The articular manifestations of progressive systemic sclerosis (scleroderma)显示文摘 | Baron M Lee P Keystone EC | 1982 | Ann Rheum Dis1982，41，： | 1 |
| 11 | Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial显示文摘 | WEINBLATT ME KEYSTONE EC FURST DE | 2003 | Arthritis Rheum2003，48，1： | 1 |
| 12 | Enhanced interleukin-1 generation by monocytes vitro is temporally linked to an early event in the onset or exaction of rheumatoid arthritis显示文摘 | Shore A Jagal S Keystone EC | 1986 | Clin ExpImmunol1986，65，2： | 1 |
| 13 | Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study显示文摘 | WEINBLATT ME KEYSTONE EC FURST DE | 2006 | Ann Rheum Dis2006，65，6： | 1 |
| 14 | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010 显示文摘 | Furst DE Keystone EC Braun J | 2011 | Ann Rheum Dis2011，70，1： | 1 |
| 15 | Consensus statement on the use of rituximab in patients with rheumatoid arthritis显示文摘 | Smolen JS Keystone EC Emery P | 2007 | Ann Rheum Dis2007，66，： | 1 |
| 16 | Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis : ARMADA 4 year extended study 显示文摘 | WEINBLATT ME KEYSTONE EC FURST DE | 2006 | Ann Rheum Dis2006，65，6： | 1 |
| 17 | Aclalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial显示文摘 | Weinblatt ME Keystone EC Furst DE | 2003 | Arthritis Rheum2003，48，3： | 1 |
| 18 | Developing an effective treatment algorithmforrheumatoid arthritis 显示文摘 | Keystone EC Smolen J van Riel P | 2012 | Rheumatology ( Oxford )2012，515，： | 1 |
| 19 | Adalimu mab,a fully human anti-tumor necrosis factor alpha monoclonal antibody,for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate:the ARMADA trial显示文摘 | Weinblatt ME Keystone EC Furst DE | 2003 | Arthritis Rheum2003，48，1： | 1 |
| 20 | The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events显示文摘 | LEOMBRUNO JP EINARSON TR KEYSTONE EC | 2009 | Ann Rheum Dis2009，68，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员